EMPIRE-2试验:分子影像引导挽救放疗剂量递增
EMPIRE-2是一项随机试验,纳入前列腺切除术后生化进展且常规影像阴性的患者,比较[18F]-fluciclovine与[68Ga]-PSMA-11 PET引导的挽救放疗剂量递增。结果显示,EMPIRE-2队列2年无事件生存率为87%,显著高于EMPIRE-1对照队列的80%(差异7.7%,p=0.01);两种PET示踪剂之间2年EFS无显著差异(87% vs 88%,p>0.9)。
要点
- PET引导的放疗剂量递增至前列腺床和/或盆腔摄取部位可改善无事件生存。
- [18F]-fluciclovine与[68Ga]-PSMA-11引导的2年EFS无显著差异。
- 剂量递增方案为前列腺床≤76.0 Gy、盆腔≤56.0 Gy。
核心结论
- 使用[18F]-fluciclovine或[68Ga]-PSMA-11 PET引导放疗剂量递增至前列腺床和/或盆腔摄取部位,与既往未剂量递增的试验相比,与无事件生存改善相关。
研究设计与样本
- EMPIRE-2是一项随机试验,纳入前列腺切除术后生化进展且常规影像阴性的患者,随机分配至[18F]-fluciclovine PET引导组(臂1)或[68Ga]-PSMA-11 PET引导组(臂2)。
- 共140例患者,臂1有59例、臂2有60例完成放疗;中位随访2.6年(IQR 1.8-4.0)。
主要发现
- EMPIRE-2总体队列2年EFS率为87%,EMPIRE-1对照队列为80%(差异7.7%,95%CI 4.7-12%,p=0.01)。
- 倾向评分加权后,2年EFS率分别为84%与73%(差异11%,95%CI 3.6-24%,p=0.01)。
- EMPIRE-2组间2年EFS率:[18F]-fluciclovine组87% vs [68Ga]-PSMA-11组88%(差异0.7%,95%CI 0.3-1.3%,p>0.9)。
关键数值与推荐
- 放疗剂量:前列腺床≤76.0 Gy,盆腔≤56.0 Gy。
- 主要终点:与EMPIRE-1中[18F]-fluciclovine放疗臂相比的2年EFS。
- 次要终点:EMPIRE-2内[18F]-fluciclovine与[68Ga]-PSMA-11的EFS比较。
临床怎么用
- 对于前列腺切除术后生化进展且常规影像阴性的患者,可考虑使用[18F]-fluciclovine或[68Ga]-PSMA-11 PET引导挽救放疗,并对PET摄取部位进行剂量递增。
局限性
- 随访时间较短,中位随访2.6年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In EMPIRE-1, [18F]-fluciclovine positron emission tomography (PET) imaging to guide salvage radiotherapy (RT) for prostate cancer recurrence after prostatectomy resulted in an improvement in event-free survival (EFS) over conventional imaging alone. The aim of EMPIRE-2 was to explore the impact of RT dose escalation to sites of uptake on PET in comparison to EMPIRE-1. METHODS: EMPIRE-2 was a randomized trial of [18F]-fluciclovine versus [68Ga]-PSMA-11 in a cohort of men with biochemical progression after prostatectomy and negative conventional imaging findings. After stratification, patients were randomized to RT guided by [18F]-fluciclovine PET (arm 1) or [68Ga]-PSMA-11 PET (arm 2). PET findings were used for treatment decisions and for RT dose escalation (≤76.0 Gy to the prostate bed and ≤56.0 Gy to the pelvis). The primary endpoint was 2-yr EFS in comparison to the [18F]-fluciclovine RT arm in EMPIRE-1. The secondary endpoint was a planned EFS comparison for [18F]-fluciclovine versus [68Ga]-PSMA-11 in EMPIRE-2. KEY FINDINGS AND LIMITATIONS: In the cohort of 140 patients, 59 randomized to arm 1 patients and 60 randomized to arm 2 completed RT. Median follow-up was 2.6 yr (interquartile range 1.8-4.0). The 2-yr EFS rates were 87% for the overall EMPIRE-2 cohort versus 80% for the EMPIRE-1 comparison cohort (difference 7.7%, 95% confidence interval [CI] 4.7-12%; p = 0.01). After propensity score weighting, the corresponding 2-yr EFS rates were 84% versus 73% (difference 11%, 95% CI 3.6-24%; p = 0.01). The 2-yr EFS rates in the EMPIRE-2 study arms were 87% for [18F]-fluciclovine versus 88% for [68Ga]-PSMA-11 (difference 0.7%, 95% CI 0.3-1.3%; p > 0.9). CONCLUSIONS AND CLINICAL IMPLICATIONS: Use of either [18F]-fluciclovine or [68Ga]-PSMA-11 imaging to guide RT dose escalation to sites of PET uptake in the prostate bed and/or pelvis was associated with an improvement in EFS in comparison to a prior trial without dose escalation.
引用
- Jani AB, Dhere VR, Goyal S, et al. [18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial. Eur Urol. 2025. PMID: 41412908. doi:10.1016/j.eururo.2025.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。